Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC
This study is a prospective, single-center, open-label, phase II clinical study for patients with recurrent or metastatics quamous cell carcinoma of the head and neck.
Head and Neck Squamous Cell Carcinoma
OTHER: Camrelizumab and SBRT
ORR, Objective Response Rate, up to approximately 2 years
PFS, Progression-Free-Survival, up to approximately 2 years|OS, OS is the time interval from the start of treatment to death due to any reason or lost of follow-up, up to approximately 2 years|DOR, Disease Control Rate, up to approximately 2 years|AE, Adverse Events, from the first drug administration to within 30 days for the last therapy
This study is a prospective, single-center, open-label, phase II clinical study for patients with recurrent or metastatics quamous cell carcinoma of the head and neck.